Technical Analysis for HMDCF - Hutchison China Ltd
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Centerline Cross | Bullish | 0.00% | |
Volume Surge | Other | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Narrow Range Bar | Range Contraction | -6.75% | |
Wide Bands | Range Expansion | -6.75% | |
Crossed Above 20 DMA | Bullish | -5.69% |
Get a Trading Assistant
Hutchison China Ltd Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Clinical Medicine Chemical Compounds Solid Tumors Breast Cancer Colorectal Cancer Immunotherapies Lung Cancer Non Small Cell Lung Cancer Small Cell Lung Cancer Hematological Malignancies Hepatocellular Carcinoma Gastric Cancer Hematological Cancers Ros1 Sarcoma Targeted Therapy Tyrosine Kinase Bemcentinib Esophageal Cancer Follicular Lymphoma Neuroendocrine Tumors Non Small Cell Lung Carcinoma Nsclc Protein Kinase Inhibitor Renal Cell Carcinoma Thyroid Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.72 |
52 Week Low | 1.61 |
Average Volume | 602 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 3.0346 |
20-Day Moving Average | 2.7819 |
10-Day Moving Average | 2.8972 |
Average True Range | 0.5419 |
RSI (14) | 51.69 |
ADX | 26.42 |
+DI | 51.6075 |
-DI | 36.0726 |
Chandelier Exit (Long, 3 ATRs) | 2.3243 |
Chandelier Exit (Short, 3 ATRs) | 3.6767 |
Upper Bollinger Bands | 3.7156 |
Lower Bollinger Band | 1.8482 |
Percent B (%b) | 0.7 |
BandWidth | 67.1268 |
MACD Line | 0.0126 |
MACD Signal Line | -0.0611 |
MACD Histogram | 0.0736 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.1500 | ||||
Resistance 3 (R3) | 3.1500 | 3.1500 | 3.1500 | ||
Resistance 2 (R2) | 3.1500 | 3.1500 | 3.1500 | 3.1500 | |
Resistance 1 (R1) | 3.1500 | 3.1500 | 3.1500 | 3.1500 | 3.1500 |
Pivot Point | 3.1500 | 3.1500 | 3.1500 | 3.1500 | 3.1500 |
Support 1 (S1) | 3.1500 | 3.1500 | 3.1500 | 3.1500 | 3.1500 |
Support 2 (S2) | 3.1500 | 3.1500 | 3.1500 | 3.1500 | |
Support 3 (S3) | 3.1500 | 3.1500 | 3.1500 | ||
Support 4 (S4) | 3.1500 |